Eva Thomas

3.1k total citations · 1 hit paper
19 papers, 1.9k citations indexed

About

Eva Thomas is a scholar working on Oncology, Cancer Research and Otorhinolaryngology. According to data from OpenAlex, Eva Thomas has authored 19 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Cancer Research and 2 papers in Otorhinolaryngology. Recurrent topics in Eva Thomas's work include Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (7 papers). Eva Thomas is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (7 papers). Eva Thomas collaborates with scholars based in United States, Argentina and France. Eva Thomas's co-authors include Gabriel N. Hortobágyi, Aman U. Buzdar, Richard L. Theriault, Thomas A. Buchholz, S. Eva Singletary, Nuhad K. Ibrahim, Linda T. Vahdat, Marjorie C. Green, Debra Frye and Terry L. Smith and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Eva Thomas

19 papers receiving 1.9k citations

Hit Papers

Significantly Higher Pathologic Complete Remission Rate A... 2005 2026 2012 2019 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
    2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →

Peers

Eva Thomas
Rabiul Islam United States
E. Mallon United Kingdom
Séverine Guiu France
Suparna Wedam United States
M. Tubiana-Hulin France
S M Edgerton United States
P. Kelly Marcom United States
Jean-Marc Extra France
Marjorie C. Green United States
Kristi McIntyre United States
Rabiul Islam United States
Eva Thomas
Citations per year, relative to Eva Thomas Eva Thomas (= 1×) peers Rabiul Islam

Countries citing papers authored by Eva Thomas

Since Specialization
Citations

This map shows the geographic impact of Eva Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Thomas more than expected).

Fields of papers citing papers by Eva Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Thomas. The network helps show where Eva Thomas may publish in the future.

Co-authorship network of co-authors of Eva Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Thomas. A scholar is included among the top collaborators of Eva Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Thomas. Eva Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kelly, Jason F., et al.. (2023). Intraoperative Radiation Therapy: A Large Integrated Health Care System’s Approach and Outcomes. The Permanente Journal. 27(1). 45–55. 1 indexed citations
2.
Neeman, Elad, Brooke Vuong, Vignesh A. Arasu, et al.. (2022). Care in the time of COVID-19: impact on the diagnosis and treatment of breast cancer in a large, integrated health care system. Breast Cancer Research and Treatment. 191(3). 665–675. 22 indexed citations
3.
Neeman, Elad, Brooke Vuong, Vignesh A. Arasu, et al.. (2022). Telehealth for Preoperative Evaluation of Patients With Breast Cancer During the COVID-19 Pandemic. The Permanente Journal. 26(2). 54–63. 3 indexed citations
4.
Rugo, Hope S., Henri Roché, Eva Thomas, et al.. (2018). Efficacy and Safety of Ixabepilone and Capecitabine in Patients With Advanced Triple-negative Breast Cancer: a Pooled Analysis From Two Large Phase III, Randomized Clinical Trials. Clinical Breast Cancer. 18(6). 489–497. 27 indexed citations
5.
6.
Vahdat, Linda T., Eva Thomas, Henri Roché, et al.. (2012). Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Supportive Care in Cancer. 20(11). 2661–2668. 32 indexed citations
7.
Kelly, Catherine M., Marjorie C. Green, Kristine Broglio, et al.. (2012). Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination With Capecitabine in Operable Breast Cancer. Journal of Clinical Oncology. 30(9). 930–935. 26 indexed citations
8.
Pivot, Xavier, Rubi K. Li, Eva Thomas, et al.. (2009). Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer. European Journal of Cancer. 45(17). 2940–2946. 20 indexed citations
9.
Bunnell, Craig A., Linda T. Vahdat, Lee S. Schwartzberg, et al.. (2008). Phase I/II Study of Ixabepilone plus Capecitabine in Anthracycline–Pretreated/Resistant and Taxane-Resistant Metastatic Breast Cancer. Clinical Breast Cancer. 8(3). 234–241. 48 indexed citations
10.
Thomas, Eva, Josep Tabernero, Monica Fornier, et al.. (2007). Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer. Journal of Clinical Oncology. 25(23). 3399–3406. 226 indexed citations
11.
Perez, Edith A., Guillermo Lerzo, Xavier Pivot, et al.. (2007). Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology. 25(23). 3407–3414. 302 indexed citations
12.
Buchholz, Thomas A., Eric A. Strom, Mary Jane Oswald, et al.. (2006). Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. International Journal of Radiation Oncology*Biology*Physics. 65(4). 1155–1160. 7 indexed citations
13.
Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685. 867 indexed citations breakdown →
14.
Morrow, Phuong K., Richard L. Theriault, G. N. Hortobágyi, et al.. (2005). Clinical outcomes of breast cancer patients with hepatitis C: A case series. Journal of Clinical Oncology. 23(16_suppl). 747–747. 3 indexed citations
15.
Yen, Tina, Kelly K. Hunt, Nadeem Q. Mirza, et al.. (2004). Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 100(5). 942–949. 40 indexed citations
16.
Yu, T., Gary J. Whitman, Howard D. Thames, et al.. (2004). Clinically Relevant Pneumonitis After Sequential Paclitaxel-Based Chemotherapy and Radiotherapy in Breast Cancer Patients. JNCI Journal of the National Cancer Institute. 96(22). 1676–1681. 44 indexed citations
17.
18.
Symmans, W. Fraser, Mark Ayers, Edwin Clark, et al.. (2003). Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma. Cancer. 97(12). 2960–2971. 140 indexed citations
19.
Thomas, Eva, et al.. (1998). Oral etoposide for patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs. 16(4). 333–335. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rabiul Islam Breakdown of academic impact, for papers by E. Mallon Breakdown of academic impact, for papers by Séverine Guiu Breakdown of academic impact, for papers by Suparna Wedam Breakdown of academic impact, for papers by M. Tubiana-Hulin Breakdown of academic impact, for papers by S M Edgerton Breakdown of academic impact, for papers by P. Kelly Marcom Breakdown of academic impact, for papers by Jean-Marc Extra Breakdown of academic impact, for papers by Marjorie C. Green Breakdown of academic impact, for papers by Kristi McIntyre
Rankless by CCL
2026